These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 33361676)

  • 1. Fabry Disease on Peritoneal Dialysis with Cardiac Involvement.
    Koga-Kobori S; Sawa N; Kido R; Sekine A; Mizuno H; Yamanouchi M; Hayami N; Suwabe T; Hoshino J; Kinowaki K; Ohashi K; Fujii T; Ubara Y
    Intern Med; 2021 May; 60(10):1561-1565. PubMed ID: 33361676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Late-onset Fabry disease: the cardiac sequela.
    Tremblay J; Kim S; Philbin E; Beers K; Lightle A; Belov D
    BMJ Case Rep; 2022 Jun; 15(6):. PubMed ID: 35680278
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Screening for Fabry disease in patients undergoing dialysis for chronic renal failure in Turkey: identification of new case with novel mutation.
    Okur I; Ezgu F; Biberoglu G; Tumer L; Erten Y; Isitman M; Eminoglu FT; Hasanoglu A
    Gene; 2013 Sep; 527(1):42-7. PubMed ID: 23756194
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of Fabry disease in female patients with late-onset hypertrophic cardiomyopathy.
    Chimenti C; Pieroni M; Morgante E; Antuzzi D; Russo A; Russo MA; Maseri A; Frustaci A
    Circulation; 2004 Aug; 110(9):1047-53. PubMed ID: 15313943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of demographic, clinical, and aetiological data of patients admitted to cardiology clinics and diagnosed with left ventricular hypertrophy in Turkish population (LVH-TR).
    Kis M; Dogan Y; Yildirim A; Güzel T; Bekar L; Akhan O; Dogdus M; Harbalıoğlu H; Karabulut D; Soydan E; Zoghi M; Ergene O;
    Acta Cardiol; 2022 Nov; 77(9):836-845. PubMed ID: 36222672
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Isolated left ventricular hypertrophy : is it a Fabry disease?].
    Barbey F; Dormond O; Monzambani V; Barbey G; Namdar M; Monney P
    Rev Med Suisse; 2020 Oct; 16(709):1886-1890. PubMed ID: 33026733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent Cerebrovascular Complications under Enzyme Replacement Therapy in a Patient with Fabry Disease on Peritoneal Dialysis.
    Muto R; Suzuki Y; Shimizu H; Yasuda K; Ishimoto T; Maruyama S; Ito Y; Mizuno M
    Intern Med; 2023 Feb; 62(4):565-569. PubMed ID: 35831104
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fabry disease presenting as apical left ventricular hypertrophy in a patient carrying the missense mutation R118C.
    Caetano F; Botelho A; Mota P; Silva J; Leitão Marques A
    Rev Port Cardiol; 2014 Mar; 33(3):183.e1-5. PubMed ID: 24661928
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevalence of Fabry Disease in Korean Men with Left Ventricular Hypertrophy.
    Kim WS; Kim HS; Shin J; Park JC; Yoo HW; Takenaka T; Tei C
    J Korean Med Sci; 2019 Feb; 34(7):e63. PubMed ID: 30804731
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enzyme replacement therapy in Fabry disease patients undergoing dialysis: effects on quality of life and organ involvement.
    Pisani A; Spinelli L; Sabbatini M; Andreucci MV; Procaccini D; Abbaterusso C; Pasquali S; Savoldi S; Comotti C; Cianciaruso B
    Am J Kidney Dis; 2005 Jul; 46(1):120-7. PubMed ID: 15983965
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cardiovascular outcomes in Fabry disease are linked to severity of chronic kidney disease.
    Talbot AS; Lewis NT; Nicholls KM
    Heart; 2015 Feb; 101(4):287-93. PubMed ID: 25381325
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A retrospective investigation to establish new screening approach for the detection of patients at high risk of Fabry disease in male left ventricular hypertrophy patients.
    Kubo T; Amano M; Takashio S; Okumura T; Yamamoto S; Nabeta T; Oikawa M; Kurisu S; Ochi Y; Sugiura K; Baba Y; Kuroiwa H; Hirota T; Yamasaki N; Ishii S; Nochioka K; Takeishi Y; Yasuda S; Tsujita K; Izumi C; Kitaoka H
    J Cardiol; 2022 Oct; 80(4):325-331. PubMed ID: 35643740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistent increase in cardiac troponin I in Fabry disease: a case report.
    Tanislav C; Feustel A; Franzen W; Wüsten O; Schneider C; Reichenberger F; Rolfs A; Sieweke N
    BMC Cardiovasc Disord; 2011 Jan; 11():6. PubMed ID: 21281467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Autopsy Findings of Heterozygous Fabry Disease with the Severe Phenotype: A Case Report.
    Hiratsuka M; Koyama K; Ito M; Sato R; Suzuki K; Ito Y; Namba-Hamano T; Hamano T
    Nephron; 2022; 146(2):203-208. PubMed ID: 34808632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Application of Genetic Testing in Unveiling the Diagnosis of Fabry Disease in a Patient with Hypertrophic Cardiomyopathy.
    Gedela M; Sharma R; DeBerg K; Stanton C
    S D Med; 2021 Apr; 74(4):150-152. PubMed ID: 34432960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Later Onset Fabry Disease, Cardiac Damage Progress in Silence: Experience With a Highly Prevalent Mutation.
    Hsu TR; Hung SC; Chang FP; Yu WC; Sung SH; Hsu CL; Dzhagalov I; Yang CF; Chu TH; Lee HJ; Lu YH; Chang SK; Liao HC; Lin HY; Liao TC; Lee PC; Li HY; Yang AH; Ho HC; Chiang CC; Lin CY; Desnick RJ; Niu DM
    J Am Coll Cardiol; 2016 Dec; 68(23):2554-2563. PubMed ID: 27931613
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Concurrent fabry disease and immunoglobulin a nephropathy: a case report.
    Zhou LN; Dong SS; Zhang SZ; Huang LW; Huang W
    BMC Nephrol; 2023 Nov; 24(1):324. PubMed ID: 37914990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The beneficial effects of long-term enzyme replacement therapy on cardiac involvement in Japanese Fabry patients.
    Hongo K; Ito K; Date T; Anan I; Inoue Y; Morimoto S; Ogawa K; Kawai M; Kobayashi H; Kobayashi M; Ida H; Ohashi T; Taniguchi I; Yoshimura M; Eto Y
    Mol Genet Metab; 2018 Jun; 124(2):143-151. PubMed ID: 29747997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fabry's disease presenting as ventricular tachycardia and left ventricular 'hypertrophy'.
    Joshi SB; Ahmar W; Lee G; Aggarwal A
    Eur J Echocardiogr; 2008 Sep; 9(5):697-9. PubMed ID: 18490300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of Fabry disease in male patients with unexplained left ventricular hypertrophy in primary cardiology practice: prospective Fabry cardiomyopathy screening study (FACSS).
    Palecek T; Honzikova J; Poupetova H; Vlaskova H; Kuchynka P; Golan L; Magage S; Linhart A
    J Inherit Metab Dis; 2014 May; 37(3):455-60. PubMed ID: 24173410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.